Toronto, Ontario--(Newsfile Corp. - June 30, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") has received a Statement of Claim filed by Sherif Louis, the former President of the Company, in the amount of approximately $530,000 for notice and bonuses that he claims are owed to him. Telo intends to file a statement of defence and counterclaim and vigorously defend the claim.
For further information, please contact:
Guido Baechler
Executive Chairman
647-477-9365
This email address is being protected from spambots. You need JavaScript enabled to view it.
MaRS Centre, South Tower
101 College Street, Suite 200
Toronto, ON, M5G 1L7
www.telodx.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's the amounts claimed and the Company's intent to defend the claim are subject to known and unknown risks, uncertainties and other factors that may cause the actual outcome to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
Last Trade: | C$0.08 |
Daily Change: | 0.005 7.14 |
Daily Volume: | 36,000 |
Market Cap: | C$7.530M |
June 18, 2025 May 15, 2025 April 10, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load